1. Containing compounds and compounds for the treatment of diseases caused by KCa3.1 inhibition. 1. Claim 1: a formula compound (1),X1 is o or NH； n is an integer from 1 to 4； R1 is hydrogen, cyano-c (o) r74191；-C (O) NR Rheteroaryl or CH₂OH； R¹ᵃ is hydrogen, C₁₋₆ alkyl,C₁₋₆ alkoxy,phenyl or heteroaryl； R¹ᵇ and R¹ᶜ are independently hydrogen, C alquilo alkyl,e. Phenyl or isobutylene, i.e. c832131 and 832626；said phenyl or said heteroaryl are optionally substituted by one or more, especially one to three times by substituents independently selected from the group consisting of hydroxy, halogen, C₁₋₆ alkyl,C₁₋₆ alkoxy,C₁₋₆ haloalkyl and C₁₋₆ haloalkoxy；R²ᵃ is hydrogen or C₁₋₆ alkyl；R²ᵇ is haloalkyl C₁₋₆,1. Lease land No. c833218331 and 832626；phenyl or heteroaryl, said phenyl or said heteroaryl are optionally substituted by one or more, especially by one or two substituents independently selected from the group consisting of hydroxy, halogen, C alquilo alkyl and C halo haloalkyl；R³ᵃ and R³ᵇ are independently from each other hydrogen, phenyl or heteroaryl, said phenyl or said heteroaryl are optionally substituted by one or more, especially one to three times by substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl and C₁₋₆ haloalkyl；Or acceptable salts on drugsUna composición que contiene los compuestos y el uso de los compuestos para el tratamiento de enfermedades mediadas por la inhibición del KCa3.1. Reivindicación 1: Un compuesto de la fórmula (1), en la que: X¹ es O ó NH； n es un número entero entre 1 y 4； R¹ es hidrógeno, ciano, -C(O)R¹ᵃ, -C(O)NR¹ᵇR¹ᶜ, heteroarilo o CH₂OH； R¹ᵃ es hidrógeno, alquilo C₁₋₆, alcoxi C₁₋₆, fenilo o heteroarilo； R¹ᵇ y R¹ᶜ son con independencia entre sí hidrógeno, alquilo C₁₋₆, fenilo o heteroarilo, dicho alquilo C₁₋₆, dicho fenilo o dicho heteroarilo están opcionalmente sustituidos por uno o más, en especial de una a tres veces por sustituyentes elegidos con independencia entre el grupo formado por hidro
